Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of apremilast in active ulcerative colitis
NL-OMON45076Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apremilast in autoimmune colitis (3 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 12. Started Sep 2016; status: active, not recruiting.
02
Drugs
apremilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON45076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45076.